Objectives. The aims of this study were to examine disease activity by the Paediatric Rheumatology International Trials Organization (PRINTO) criteria for inactive disease and the Myositis Disease Activity Assessment Tool (MDAAT) in JDM patients after long-term follow-up and to identify predictors of these outcomes.
Introduction JDM is a rare, autoimmune disease of childhood characterized by proximal symmetrical muscle weakness and characteristic skin lesions, but other organs can also be affected [1] . JDM outcomes have improved with advances in medical treatment; the mortality rate has decreased to <2%, but 6090% of patients develop disease damage after 717 years of follow-up [25] . However, there is still limited information about disease activity (potentially reversible with treatment) after long-term follow-up.
Slightly different core sets for disease activity have been developed by the Paediatric Rheumatology International Trials Organization (PRINTO) [6] and the International Myositis Assessment and Clinical Studies (IMACS) group [7] . The Myositis Disease Activity Assessment Tool (MDAAT) is a comprehensive tool developed by IMACS for evaluating global and extramuscular disease activity [7] . Part of this tool has been used in a multinational, cross-sectional study with a mean 7.7 years after disease onset that included 392 JDM patients from Latin America and Europe [2] . In that study, 41% of patients were found to have active disease at follow-up measured by MDAAT and 61% measured by another tool for global disease activity, the JDM DAS [8] . However, it was not investigated whether these findings were associated with each other or with other disease activity and damage measures; also, the patients were not classified according to a clinically inactive disease state.
Information about an inactive disease state in JDM and possible prediction of such is obviously important for patients, parents and physicians. However, there is no gold standard or biomarker available for determining if a patient has reached this disease state, thus different studies have used different sets of criteria, making them hard to compare [2, 5, 9, 10] . Recently, PRINTO has defined datadriven criteria for clinically inactive disease on and off therapy designed for both research and clinical practice [11] . A recent review stated the necessity of testing the criteria in patients with variable disease activity [12] ; however, to our knowledge, the criteria have not yet been applied in an independent JDM cohort. Thus there is very limited information about the prevalence of clinically inactive disease in JDM after long-term follow-up.
We have established a retrospective inception cohort of 59 Norwegian JDM patients diagnosed in the period 19702006 and performed a follow-up study after a median 16.8 years. This cohort has been thoroughly described with regard to mortality and cumulative organ damage [4], muscular outcome [13] , pulmonary involvement [14] , cardiac dysfunction [15, 16] and quality of life [17] . We now wanted to explore disease activity measured by the MDAAT and the prevalence of clinically active disease by the PRINTO criteria in these patients and see whether these outcomes were associated with each other and other validated IMACS and PRINTO disease activity and damage tools. We also wanted to investigate whether the outcomes could be predicted by disease characteristics during the disease course.
Patients and methods

Patients
A retrospective inception cohort of 59 Norwegian JDM patients diagnosed between January 1970 and June 2006 was established as previously described in detail [4] . Symptom onset was defined as the first muscle or skin symptom clearly related to JDM and follow-up time was the time from symptom onset to follow-up. The inclusion criteria were a probable or definite diagnosis of DM according to the BohanPeter criteria [18] , disease onset before 18 years of age and a minimum of 24 months follow-up time. Of the 59 patients, 36 (61%) were female and 57 patients were of European and 2 of Asian origin [4] . Informed consents were obtained from all patients and/or parents according to the Declaration of Helsinki. The study was approved by the South-Eastern Regional Ethics Committee for Medical Research.
Clinical assessment and chart review
One follow-up visit of all patients was performed between September 2005 and June 2008 at Oslo University Hospital and the follow-up time was 16.8 years (range 2.038.1). The follow-up visit included clinical examination (muscles, skin, joints and heart) by a single physician (H.S.), muscle endurance testing (physiotherapist), laboratory measures, HLA-DRB1 alleles [13] and patientreported questionnaires. In order to identify predictors of disease activity at follow-up, data were collected retrospectively by chart review (H.S.) before the follow-up visit, with focus on the first year after diagnosis. Also, the use of immunosuppressive medication (prednisolone and/or DMARDs), including cumulative prednisolone dose, was assessed for the entire disease course. When necessary, other hospitals/doctors were contacted for copies of patients' charts [4].
Myositis disease activity assessment tool
The MDAAT, a combined tool consisting of the myositis disease activity assessment visual analogue scale (MYOACT) and the Myositis Intention-to-Treat Activity Index (MITAX), was scored at the follow-up visit. The MDAAT measures potentially reversible disease activity due to the myositis disease process in muscle and six extramuscular organ systems (domains) within the last 4 weeks [7, 19] . MYOACT extramuscular (range 060) and MYOACT total (range 070) in addition to MITAX extramuscular (054) and MITAX total (063) were scored as presented on the IMACS Web site (http:// www.niehs.nih.gov/research/resources/collab/imacs/dis easeactivity.cfm and [20] ) and higher scores means higher disease activity.
Other disease characteristics
At follow-up, disease activity was also measured by the DAS (range 020), which consists of DAS muscle (range 011) and DAS skin (range 09) [8] . The physicians' global assessment of disease activity (PhysGlobAct) and the patient/parents' global assessment of disease activity (PtsGlobAct) [21] were recorded on a 010 cm visual analogue scale (VAS). Muscle strength was measured by the Manual Muscle Test (MMT-8; range 080) [22] and functional ability/muscle endurance by the Child Myositis Assessment Scale (CMAS; range 052) [23] , as previously described. The HAQ [24] and the Child HAQ [25] were used to measure physical function in patients aged 518 years (n = 39) and <18 years (n = 20), respectively. Healthrelated quality of life was measured by the 36-item Short Form health Survey (SF-36) physical component score www.rheumatology.oxfordjournals.org (PCS) [26, 27] in patients 514 years of age (n = 48) and cumulative organ damage by the Myositis Damage Index (MDI) [4, 7] . In order to identify possible predictors of high disease activity at follow-up, the DAS and MDI were also scored retrospectively from the first year after diagnosis, as previously described [4].
The PRINTO criteria for clinically inactive disease on and off therapy The PRINTO criteria were used to define clinically inactive disease with the presence of at least three of four of the following: creatine kinase (CK) 4150, CMAS 548, MMT-8 578 and PhysGlobAct 40.2 [11] . By these criteria, patients were divided into clinically inactive and active disease.
Statistical analyses
Continuous normally distributed variables were reported as mean (S.D.) and continuous non-normally distributed variables as median [interquartile range (IQR)] unless otherwise stated. Differences in characteristics between two patient groups were tested by Student's unpaired two-tailed t-test for continuous normally distributed variables and by MannWhitney test for continuous not normally distributed variables. Chi-square test was used to test differences between two groups for categorical variables. Spearman's correlation coefficients (r sp ) were used to analyse possible correlates between continuous variables and the strength of correlation was based on the absolute value of r sp : weak r sp , 50.2<0.3; moderate, 50.3<0.7; strong 50.7.
In order to identify possible risk factors for disease activity at follow-up (clinically active disease by the PRINTO criteria and MYOACT total and MYOACT extramuscular dichotomized to scores >0.2 or 40.2), initial univariate logistic regression analyses were performed on the relationship between these outcome variables and the following independent variables: time from symptom onset to diagnosis, low age at diagnosis (<9 years), initial prednisolone dose >1 mg/kg, started DMARD within the first year after diagnosis, HLA-DRB1 alleles, MDI and DAS (skin, muscle and total) assessed at the first year after diagnosis, as well as the following variables during the disease course: cumulative prednisolone dose, use of MTX, use of antimalarials, calcinosis and arthritis. Independent variables with a Pvalue 40.15 were included in the multivariate regression analyses by backward elimination of possible predictors, and both gender and follow-up time were included as controlling factors. Data on the strength of the associations were given as odds ratios (ORs) with 95% CIs. A P-value <0.05 was considered significant. SPSS version 18.0 (IBM, Armonk, NY, USA) was used for statistical analyses.
Results
Disease activity by MDAAT and associations with disease characteristics
For MITAX and MYOACT, the organ systems with detectable disease activity were, in declining order, skin, skeletal and constitutional/muscular ( Table 1) . The MYOACT and MITAX were strongly correlated, both as a total score and also in domain-to-domain correlations. Of the 59 patients, 16 (27%) had a MITAX total = 0; when excluding the skin domain from the score, 34 (58%) had a MITAX totalskin = 0. When comparing patients diagnosed before and after 1990, 18/29 (62%) vs 25/30 (83%) had MYOACT >0.2 (P = 0.066).
MYOACT total and MYOACT extramuscular showed strong correlations with the DAS total and PhysGlobAct (Table 2 and Fig. 1A and B) and a moderate correlation with the PtsGlobAct, CMAS, MMT-8, SF-36 PCS and CHAQ/HAQ (Table 2) . Neither MYOACT total nor MYOACT extramuscular correlated with gender, age at follow-up, follow-up time, time from symptom onset to diagnosis or any muscle enzyme (data not shown).
Of the 59 patients, 17 (29%) used anti-inflammatory medication at follow-up, including prednisolone (n = 10), MTX (n = 9), antimalarials (n = 8), ciclosporin (n = 3), AZA (n = 1) and infliximab (n = 1). Patients on medication (n = 17) had a higher MYOACT total than patients off medication (n = 42) [1.9 (S.D. Disease activity variables included in the PRINTO composite score are shown in Table 3 . All variables, except for CK, clearly differed between inactive and active patients. Compared with clinically active patients, inactive patients had lower disease activity measured by MDAAT and DAS (Table 3 and Fig. 1C and D) . Inactive patients had higher SF-36 PCS (Fig. 1E) and lower CHAQ/HAQ scores, whereas no significant difference in PtsGlobAct scores was found between the groups (Table 4 ). Inactive patients also had lower MDI scores than active patients (Table 3 and Fig. 1F) .
Of clinically inactive patients, 14/29 (48%) had a MITAX = 0 compared with 2/30 (7%) active patients (P < 0.001). When excluding the skin domain from the MITAX total score, 25/29 (86 %) inactive patients had a MITAX totalskin = 0 compared with 9/30 (30%) active patients (P < 0.001).
Predictors for clinically active disease and high MYOACT at follow-up MDI assessed at 6 and 12 months after diagnosis were identified as predictors for active disease and MYOACT total >0.2, respectively (Table 4) . Also, calcinosis during the disease course predicted MYOACT total >0.2, whereas age <9 years at diagnosis and started DMARD within the first year after diagnosis predicted clinically active disease. Of the controlling variables, shorter follow-up time was associated with MYOACT total >0.2. When analysing MYOACT extramuscular >0.2 as an outcome, calcinosis during disease course was identified as a predictor, HLA-DRB1*0301 was univariately associated with the outcome [OR 4.24 (95% CI 1.06, 16.97)], but was not identified as a predictor in the final model.
Discussion
At a median 16.8 years after disease onset, 51% of JDM patients were clinically active and 73% of patients had measurable but mostly low disease activity by MDAAT. Clinically active disease and disease activity by the MDAAT were associated with each other and with most other validated IMACS/PRINTO disease activity tools. Both outcomes were predicted by early damage; also a high MYOACT was predicted by calcinosis during the disease course and an active disease state by younger age at diagnosis and started DMARDs within the first year after diagnosis. A shorter follow-up time was associated with a high MYOACT. To our knowledge, this is the first study to comprehensively examine the prevalence of and predictors for disease activity after long-term follow-up in JDM utilizing standardized tools.
We have previously discussed the representativeness of our cohort with regard to female predominance, age at diagnosis, duration of untreated disease, medication and skin and muscle manifestations at symptom onset [4]. Since our cohort was established as a retrospective inception cohort, we are not biased towards patients still followed in the hospital system. We found that 51% of patients were active as defined by the PRINTO criteria and no difference in the frequency of active disease was found in patients diagnosed before and after 1990. To our knowledge, these criteria have not previously been applied in an independent JDM cohort. Measurable disease activity (MYOACT total >0.2) was found in 73% of our patients, compared with 41% of JDM patients in a large multinational study [2] . In both www.rheumatology.oxfordjournals.org studies the four most commonly scored organ systems (MYOACT >0.2) were skin, skeletal, muscle and constitutional. The higher frequency of disease activity in our cohort might be due to our comprehensive examination of disease activity. However, we cannot rule out that the tool has been applied differently. We had a follow-up period that was twice as long compared with the multinational study (median 16.8 vs mean 7.7 years), and we have previously shown that our patients diagnosed before 1990 were treated less aggressively than those diagnosed after 1990 [4] . In spite of that, a shorter follow-up time was associated with higher MYOACT in the multivariate analyses, possibly reflecting the natural course of the disease, with higher disease activity early in the disease course.
Early damage present the first year after diagnosis was identified as a predictor of both high MYOACT and clinically active disease, and we have previously identified early damage as a predictor of both cumulative organ damage [4] and unfavourable muscle outcome [13] . Started DMARDs within the first year after diagnosis was also found to predict clinically active disease at follow-up, which we believe is an example of confounding by indication; the sickest patients were treated most aggressively and thus had a tendency to receive DMARDs. Also, calcinosis during the disease course was found to be a predictor of high MYOACT. Interestingly, previous studies have identified a chronic disease course as a predictor of calcinosis [2, 28] ; in our clinical setting, calcinosis might just be a marker of a chronic disease course. In a previous JDM study, a chronic disease course and an insidious disease onset were shown to predict ongoing disease activity after a mean 7.7 years [2], while no predictors for chronic disease course were identified in another study [29] . A young age at diagnosis (<9 years) was also a predictor for clinically active disease; a previous report has shown that patients younger than 3 years have a tendency towards a shorter duration of active disease. Surprisingly, the presence of HLA-DRB1*0301 was univariately associated with a high MYOACT extramuscular score. This allele is established as a predisposing genetic factor for JDM [30] , also reported by us [13] , but, to our knowledge, has not been described as a severity factor in JDM.
Given the cross-sectional design of our study, information about disease activity before the follow-up visit was collected retrospectively, and this is a limitation. However, despite comparable follow-up times, clinically active patients had used more prednisolone than inactive patients during the disease course. This finding indicates that physicians treating these patients before the follow-up visit also have evaluated clinically active patients as more active and, accordingly, cumulative prednisolone dose might in this setting be a surrogate marker for sustained disease activity. Additionally, clinically active patients had more organ damage at follow-up, which might reflect that the measured damage is a result of sustained disease activity. On the other hand, we cannot rule out that a high cumulative prednisolone dose per se could have contributed to the measured damage.
All variables included in the PRINTO composite score differed clearly between the groups, except for CK. It is known that muscle enzymes are poor biomarkers for disease activity after long disease duration [31] , however, we found slightly higher lactate dehydrogenase (LDH) in active patients compared with inactive patients. LDH has previously been reported to correlate better with disease activity than CK in JDM [32] .
We found highly significant associations between clinically inactive disease and low disease activity measured by global disease activity tools (MDAAT and DAS).
However, only 48% of inactive patients had a MITAX = 0, but this percentage increased to 86% when we excluded the skin domain from the MITAX score. This finding indicates that MITAX total is mainly driven by skin involvement when applied after long-term follow-up. Even though the PtsGlobAct did not differ between inactive and active patients, physical function and health-related quality of life were better in the first group. These findings support that the PRINTO criteria also reflect the patient's perspective after long disease duration [12] . Approximately half of patients classified as clinically active did not use prednisolone or DMARDs, which might suggest that either patients were insufficiently treated or the criteria classified inactive patients as active.
The MYOACT strongly correlated with the MITAX both as total score and organ by organ, which is in accordance with results from an MDAAT validation study performed on adult myositis patients [19] . Interestingly, in our study MYOACT total also correlated strongly with DAS total , but correlations with DAS muscle and DAS skin were moderate, indicating that MYOACT and DAS reveal additional aspects of disease activity in JDM. The association between MDAAT and both patient-reported measures and use of medication also supports the validity of the tool used after long-term follow-up.
In conclusion, 5173% of JDM patients had active disease after a median 16.8 years follow-up time, a frequency that is higher than previously reported. The MDAAT and clinically active disease by the PRINTO criteria were moderately to highly associated with each other, and both outcomes were predicted by early damage. Hopefully, further improvements in medical treatment will provide a reduced risk of persistent disease activity in the future.
Rheumatology key messages
. After median 16.8 years' follow-up, 5173% of JDM patients had detectable disease activity. . Damage present the first year after diagnosis predicted active disease in JDM patients after long-term follow-up. . In JDM, Paediatric Rheumatology International Trials Organization criteria and the Myositis Disease Activity Assessment Tool were associated but revealed different aspects of disease activity.
